4D MOLECULAR THERAPEUTICS INC. - COMMON STOCK

4DMT to Participate in Upcoming Investor Conferences and Ophthalmology Innovation Summit XIV

14 11 2024 08:00:00 提供 Nasdaq GlobeNewswire

4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones

13 11 2024 16:05:00 提供 Nasdaq GlobeNewswire

4DMT Announces Presentation at the 2024 North American Cystic Fibrosis Conference

23 9 2024 08:00:00 提供 Nasdaq GlobeNewswire

4DMT Highlights Robust and Durable Clinical Activity for 4D-150 and Design of 4FRONT Phase 3 Program at 4D-150 Wet AMD Development Day

18 9 2024 16:05:00 提供 Nasdaq GlobeNewswire

4DMT Announces Presentations at Upcoming Retina Conferences

05 9 2024 08:00:00 提供 Nasdaq GlobeNewswire

4DMT to Participate in the 2024 Cantor Global Healthcare Conference

03 9 2024 08:00:00 提供 Nasdaq GlobeNewswire

4DMT to Host 4D-150 Wet AMD Development Day on September 18, 2024

27 8 2024 08:00:00 提供 Nasdaq GlobeNewswire

4DMT to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

12 8 2024 08:00:00 提供 Nasdaq GlobeNewswire

4DMT Reports Second Quarter 2024 Financial Results and Operational Highlights

08 8 2024 16:05:01 提供 Nasdaq GlobeNewswire

4DMT Advances Leadership in Large Market Ophthalmology with Senior Management Hires and Formation of Ophthalmology Advisory Board

05 8 2024 08:00:00 提供 Nasdaq GlobeNewswire

4DMT Announces Positive Phase 2 PRISM Interim Results for Intravitreal 4D-150 in a Broad Wet AMD Population Affirming Favorable Safety Profile and Robust Clinical Activity

17 7 2024 05:00:00 提供 Nasdaq GlobeNewswire

4DMT Announces FDA Clearance of IND Application for 4D-175 Genetic Medicine for the Treatment of Geographic Atrophy

24 6 2024 08:00:00 提供 Nasdaq GlobeNewswire

4DMT to Present Initial Interim 24-week Landmark Analysis from the 4D-150 Phase 2 PRISM Population Extension Cohort in a Broad Wet AMD Population at ASRS and Host a Corporate Webcast

18 6 2024 08:00:00 提供 Nasdaq GlobeNewswire

4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting

08 6 2024 16:30:00 提供 Nasdaq GlobeNewswire

4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Modulator-Ineligible/-Intolerant Cystic Fibrosis at 47th European Cystic Fibrosis Conference

06 6 2024 07:30:00 提供 Nasdaq GlobeNewswire

4DMT Announces Presentations at Clinical Trials at the Summit 2024 Meeting

04 6 2024 08:00:01 提供 Nasdaq GlobeNewswire

4DMT to Participate in Upcoming Investor Conferences

03 6 2024 08:00:00 提供 Nasdaq GlobeNewswire

4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 47ᵗʰ European Cystic Fibrosis Conference

30 5 2024 08:00:00 提供 Nasdaq GlobeNewswire

4DMT Reports First Quarter 2024 Financial Results and Operational Highlights

09 5 2024 16:05:00 提供 Nasdaq GlobeNewswire

4DMT to Participate in Upcoming Investor Conference

07 5 2024 08:00:01 提供 Nasdaq GlobeNewswire